Autoimmune Disease Clinical Trials

118 recruitingLast updated: June 17, 2026

There are 118 actively recruiting autoimmune disease clinical trials across 25 countries. Studies span Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 4, Phase 3. Top locations include Beijing, Beijing Municipality, China, Hangzhou, Zhejiang, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Autoimmune Disease Trials at a Glance

118 actively recruiting trials for autoimmune disease are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Not Applicable with 24 trials, with the heaviest enrollment activity in Beijing, Hangzhou, and Houston. Lead sponsors running autoimmune disease studies include The Children's Hospital of Zhejiang University School of Medicine, Tongji Hospital, and Assistance Publique - Hôpitaux de Paris.

Browse autoimmune disease trials by phase

Treatments under study

About Autoimmune Disease Clinical Trials

Looking for clinical trials for Autoimmune Disease? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Autoimmune Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Autoimmune Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 118 trials

Recruiting

Deciphering the Genetic Architecture of Autoimmune Diseases

Autoimmune Diseases
National Human Genome Research Institute (NHGRI)300 enrolled2 locationsNCT06948110
Recruiting

Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

Neuromyelitis OpticaMultiple SclerosisDemyelinating Autoimmune Diseases, CNS
Icahn School of Medicine at Mount Sinai170 enrolled1 locationNCT05982925
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting

The Mycophenolate Pregnancy Registry

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
Genentech, Inc.500 enrolled1 locationNCT01733082
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1

Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers

Autoimmune Diseases
Daewoong Pharmaceutical Co. LTD.84 enrolled1 locationNCT06736587
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 2

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Hematopoietic and Lymphatic System NeoplasmAutoimmune DiseaseRespiratory Syncytial Virus Infection
Fred Hutchinson Cancer Center60 enrolled3 locationsNCT06817889
Recruiting
Phase 2

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

Kidney DiseasesImmune System DiseasesAutoimmune Diseases+3 more
University of Leicester24 enrolled6 locationsNCT04663204
Recruiting
Early Phase 1

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

Moderate to Severe Refractory Autoimmune Diseases
Vivacta Biotechnology (Shanghai) Co., Ltd.22 enrolled1 locationNCT07614191
Recruiting
Phase 1

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Psoriasis (PsO)+3 more
Seismic Therapeutic AU Pty Ltd24 enrolled2 locationsNCT07455578
Recruiting
Phase 1

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting
Early Phase 1

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology22 enrolled1 locationNCT07333118
Recruiting

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

MelanomaRheumatoid ArthritisAnkylosing Spondylitis+10 more
M.D. Anderson Cancer Center125 enrolled1 locationNCT04751396
Recruiting

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Genetic DiseaseAutoimmune DiseasesNeurological Diseases or Conditions+1 more
Imagine Institute500 enrolled32 locationsNCT07040774
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Not Applicable

Testimonials and Navigation in Rheumatology

Autoimmune DiseasesRheumatologic Disease
University of Alabama at Birmingham1,170 enrolled3 locationsNCT06469788
Recruiting

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

VasculitisSystemic Lupus Erthematosus (SLE)Rheumatic Diseases+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre100 enrolled1 locationNCT07278609
Recruiting
Not Applicable

Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

Celiac DiseaseAutoimmune DiseasesGluten Sensitivity
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud51 enrolled1 locationNCT07362654
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

healthy adult participantsHealthy ParticipantsHealthy Volunteers+4 more
BeiGene211 enrolled13 locationsNCT06342713